{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:45:06Z","timestamp":1791099906311,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4755,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.exphem.2009.04.002","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T05:09:18Z","timestamp":1242882558000},"page":"649-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Acute myelogenous leukemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Joshua L.","family":"Shipley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Butera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2009.04.002_bib1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2005.06.090","article-title":"Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study","volume":"23","author":"Farag","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Pretreatment cytogenetcs add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukemia associated with core binding factor translocations","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib5","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2141.2006.06229.x","article-title":"Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukemia with t(8;21)\/AML1-ETO","volume":"134","author":"Kuchenbauer","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/asheducation-2006.1.169","article-title":"Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia","author":"Mrozek","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2009.04.002_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2006.06310.x","article-title":"Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukemia","volume":"135","author":"Ichikawa","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib8","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study","volume":"24","author":"Paschka","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","article-title":"Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?","volume":"109","author":"Mrozek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib10","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood.V78.10.2520.2520","article-title":"A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B","volume":"78","author":"Dillman","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib11","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","article-title":"A randomized investigation of high-dose versus standard \u2013dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia; A Southwest Oncology Group Study","volume":"88","author":"Weick","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib12","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib13","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood.V78.10.2520.2520","article-title":"A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B","volume":"78","author":"Dillman","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V75.1.27.27","article-title":"Etoposide in acute nonlymphocytic leukemia","volume":"75","author":"Bishop","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","article-title":"Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia","volume":"79","author":"Wiernik","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib18","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","article-title":"Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia","volume":"77","author":"Berman","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib19","first-page":"177","article-title":"Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia. Lederle Cooperative Group","volume":"4","author":"Arlin","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib20","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood.V98.13.3575","article-title":"Comparison of idarubicin + ara-c-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts","volume":"98","author":"Estey","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2141.2005.05745.x","article-title":"Multicenter phase III trial of fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C, and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients","volume":"131","author":"Russo","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib22","article-title":"Daunorubicin and cytarabine compared with daunorubicin, cytarabine and the MDR1 reversal agent PSC-833 in elderly patients with acute myelogenous leukemia","volume":"104","author":"Van Der Holt","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib23","volume":"108","author":"Cripe","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib24","article-title":"The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 Trial","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0889-8588(18)30257-0","article-title":"Treatment of the newly diagnosed adult with de novo acute myeloid leukemia","volume":"7","author":"Stone","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2009.04.002_bib26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.1990.8.7.1199","article-title":"Postremission chemotherapy for adults with acute myelogenous leukemia: improvement survival with high-dose cytarabine and daunorubicin consolidation treatment","volume":"8","author":"Champlin","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.V79.8.1924.1924","article-title":"Varying intensity postremission therapy in acute myeloid leukemia","volume":"79","author":"Cassileth","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2404122","article-title":"Intensive consolidation verses oral maintenance therapy in patients 61 years or older with in acute myelogenous leukemia in first remission: results of second randomization of AML HD98-B treatment trial","volume":"20","author":"Schlenk","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib29","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission","volume":"339","author":"Cassileth","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.exphem.2009.04.002_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous or allogeneic bone marrow transplantation compared Cawith intensive chemotherapy in acute myelogenous leukemia","volume":"332","author":"Zittoun","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2009.04.002_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2009.04.002_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jnci\/djh003","article-title":"Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis","volume":"96","author":"Nathan","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2009.04.002_bib33","first-page":"2978","article-title":"Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia","volume":"90","author":"Harousseau","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib34","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.11240","article-title":"Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de nova acute myelogenous leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.04.002_bib35","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib36","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1365-2141.1998.896hm3674.x","volume":"102","author":"Keating","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1):an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC","volume":"118","author":"Burnett","year":"2002","journal-title":"AML trial. Br J of Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.leu.2401568","article-title":"Treatment of relapsed and refractory acute myelogenous leukemia","volume":"14","author":"Estey","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2141.2004.05318.x","article-title":"Biology and management of relapsed acute myeloid leukemia","volume":"129","author":"Craddock","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib41","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognosic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V76.3.473.473","article-title":"High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy","volume":"76","author":"Brown","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.1988.6.2.213","article-title":"Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia\u2212an active and well-tolerated regimen","volume":"6","author":"Ho","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2001.02551.x","volume":"112","author":"Jackson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.annonc.a010796","article-title":"Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience","volume":"7","author":"Vignetti","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib46","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbmt.2006.07.015","article-title":"Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study","volume":"12","author":"Chantry","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2009.04.002_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2141.1999.01713.x","article-title":"Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia","volume":"107","author":"Grigg","year":"1999","journal-title":"Br J Haematol"},{"issue":"3-4","key":"10.1016\/j.exphem.2009.04.002_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/10428190109057983","article-title":"Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients","volume":"41","author":"Boiron","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2009.04.002_bib49","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/00007890-199710150-00014","article-title":"HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry","volume":"64","author":"Mori","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2009.04.002_bib50","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","article-title":"Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia","volume":"21","author":"Bertz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib51","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells","volume":"97","author":"VanDer Velden","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukaemia therapy","volume":"132","author":"Tsimberidou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib54","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/1097-0142(19891101)64:9<1812::AID-CNCR2820640909>3.0.CO;2-I","article-title":"The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes","volume":"64","author":"Aul","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.04.002_bib55","first-page":"172","article-title":"Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia","volume":"50","author":"Robak","year":"2003","journal-title":"Neoplasma"},{"key":"10.1016\/j.exphem.2009.04.002_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment","author":"Small","year":"2006","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2009.04.002_bib57","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"15","author":"O'Farrell","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2009.04.002_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib59","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.leukres.2003.11.004","article-title":"Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia","volume":"28","author":"O'Farrell","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2009.04.002_bib60","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","article-title":"A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia","volume":"102","author":"Fiedler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib61","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2002-10-3023","article-title":"SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients refractory acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Giles","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib62","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib63","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib65","first-page":"22","article-title":"Oral PKC412 has activity in patients with mutant FLT3 acute myeloid leukemia: a phase II trial","author":"Stone","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib66","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib67","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","article-title":"In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic toxic effects","volume":"104","author":"Levis","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib68","article-title":"A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition","volume":"106","author":"Levis","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib69","volume":"108","author":"Stone","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib70","article-title":"Phase 1\/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib71","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00062752-200207000-00008","article-title":"Ras processing as a therapeutic target in hematologic malignancies","volume":"9","author":"Le","year":"2002","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib72","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1600-0609.2004.00336.x","article-title":"The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro","volume":"73","author":"Korycka","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib73","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/sj.leu.2403063","article-title":"Effects of farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis","volume":"17","author":"Liesveld","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib74","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A phase 2 study of the farnesyl transferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib75","article-title":"Farnesyl transferase inhibitor (Tipifarnib, Zarnestra) in combination with standard chemotherapy with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high risk myelodysplastic syndrome","volume":"108","author":"Alvarez","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib76","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0b013e31803c7359","article-title":"DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies","volume":"13","author":"Fandy","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.exphem.2009.04.002_bib77","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib78","article-title":"5-Azacytidine induces hematologic responses in a high proportion of patients with acute myeloid leukemia refractory to or not eligible for intensive chemotherapy","volume":"108","author":"Al-Ali","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib79","article-title":"Final results of a phase 1 study of the histone deacetylase inhibitor Vorinostat (suberoyanilide hydroxamic acid SAHA), in patients with leukemia and myelodysplastic syndrome","volume":"106","author":"Garcia-Manero","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.21552","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia","volume":"106","author":"Kuendgen","year":"2006","journal-title":"Cancer"},{"issue":"Suppl 13","key":"10.1016\/j.exphem.2009.04.002_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","article-title":"Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia","volume":"84","author":"Kuendgen","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib82","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib83","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.leu.2404050","article-title":"Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Maslak","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib84","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib85","article-title":"Phase 1\/2 study of the oral isotype selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients with high-risk myelodysplastic syndrome or acute myelogenous leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib86","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2003-07-2490","article-title":"Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies","volume":"104","author":"Mahadevan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib87","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib88","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","article-title":"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)","volume":"22","author":"Greenberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib89","first-page":"595","volume":"98","author":"Cripe","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cco.0000142074.67968.eb","article-title":"Bcl-2 antisense therapy in hematologic malignancies","volume":"16","author":"Chanan-Khan","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation-2005.1.143","article-title":"New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents","author":"Tallman","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2009.04.002_bib92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","article-title":"Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia","volume":"101","author":"Marcucci","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib93","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1200\/JCO.2005.09.118","article-title":"Phase 1 study of oblimersen sodium, an antisense to bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2009.04.002_bib94","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib95","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.leu.2404213","article-title":"Phase 1 study of PTK787\/ZK222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome","volume":"20","author":"Roboz","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2009.04.002_bib96","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2005.10.024","article-title":"The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome","volume":"30","author":"Giles","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2009.04.002_bib97","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib98","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","article-title":"A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia","volume":"102","author":"Fiedler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib99","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","article-title":"Targeting vascular endothelial growth factor for relapsed and refractory adult acute myeloid leukemias: therapy with sequential 1 beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab","volume":"10","author":"Karp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2009.04.002_bib100","article-title":"Bevacizumab reduces VEGF expression in patients with relapsed and\/or refractory acute myeloid leukemia without clinical antileukemic activity","volume":"108","author":"Zahiragic","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.exphem.2009.04.002_bib101","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2003.04639.x","article-title":"Single agent thalidomide in patients with relapsed or refractory acute myeloid leukemia","volume":"123","author":"Thomas","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2009.04.002_bib102","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.11180","article-title":"A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2009.04.002_bib103","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","article-title":"Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-c) in relapsed and refractory acute leukemias","volume":"105","author":"Faderl","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib104","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2009.04.002_bib105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia in patients 50 years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X09001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:27:10Z","timestamp":1759566430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X09001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0301472X09001301"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2009.04.002","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2009.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}